News | January 30, 2013

Artery Disease Faces Future Enemy in Bioabsorbable Stents

Bioresorbable Stent GlobalData Peripheral Artery Disease

January 30, 2013 — Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once the medical world has provided enough clinical data and prices are lowered, states a new report by research and consulting firm GlobalData.

Stent technology has evolved over the years to address the challenges of treating arterial diseases, and the new report looks at bioabsorbable stents, which offer temporary scaffolding to the vessel and then disappear over time, leaving behind a healed artery. Bioabsorbable stents are in their infancy and there is a long road ahead before widespread adoption into clinical practice is reached, but GlobalData believes the technology holds the potential to revolutionize patient treatment.

“Coronary and peripheral artery diseases affect over 7 million and 8 million people above the age of 65 years respectively, and will continue to increase in the future,” states GlobalData’s analyst for cardiovascular devices Priya Madhavan, MS.

Although traditional stents improve patient prognosis in comparison to invasive cardiac surgeries, complications such as restenosis and thrombosis remain a concern, and there is a demand from physicians to reduce the need for dual anti-platelet therapy, required when implanting bare metal and drug-eluting stents. Fully degradable and absorbable stents tackle all these concerns, and could potentially ensure quality long-term results for the patient.

Although bioabsorbable stents offer several advantages, GlobalData predicts that adoption of this technology will be slow in the United States and Europe, as a lack of long-term clinical data and high prices remain barriers to public and professional acceptance.

“Bioabsorbable stent technology is novel and exciting, however, the technology is in the early stages of development and has a long road ahead before it becomes a standard of care in clinical practice,” Madhavan said. “As bioabsorbable stents receive FDA approval, the U.S. will acquire market share and steadily become the largest market through 2018 and beyond.”

GlobalData estimates bioabsorbable stent sales to be $4.2 million in 2012 across the United States, France, Germany, Italy, Spain and the U.K., growing to more than $700 million by the end of 2018 at a Compound annual growth rate (CAGR) of 172 percent. The launch of fully bioabsorbable stent products currently in the pipeline, such as the DREAMS stent developed by Biotronik, and the FDA approval and launch of Absorb BVS and Remedy in the United States are expected to significantly expand options within the bioabsorbable stent market.

For more information:

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init